# The Safety and Efficacy of Roflumilast Foam in HS

> **NCT07263230** · PHASE2 · RECRUITING · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 20 (estimated)

## Conditions studied

- Hidradenitis Suppurativa (HS)

## Interventions

- **DRUG:** Roflumilast 0.3% topical foam

## Key facts

- **NCT ID:** NCT07263230
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2028-03
- **Final completion:** 2028-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07263230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07263230, "The Safety and Efficacy of Roflumilast Foam in HS". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07263230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*